FY2025 Earnings Estimate for Merus Issued By Leerink Partnrs

Merus (NASDAQ:MRUS) – Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Merus in a research note issued on Monday, December 2nd. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of ($4.75) per share for the year, up from their previous forecast of ($4.82). The consensus estimate for Merus’ current full-year earnings is ($3.89) per share. Leerink Partnrs also issued estimates for Merus’ FY2026 earnings at ($2.33) EPS and FY2027 earnings at $4.03 EPS.

A number of other brokerages also recently weighed in on MRUS. HC Wainwright reiterated a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Monday, December 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Monday, December 2nd. UBS Group assumed coverage on Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 price objective for the company. The Goldman Sachs Group assumed coverage on Merus in a research report on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. Finally, Guggenheim restated a “buy” rating and set a $109.00 price objective (down previously from $111.00) on shares of Merus in a research report on Tuesday. One research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Merus currently has an average rating of “Buy” and a consensus target price of $85.27.

Merus Trading Up 1.8 %

Shares of NASDAQ MRUS opened at $44.65 on Thursday. Merus has a twelve month low of $22.27 and a twelve month high of $61.61. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of -11.30 and a beta of 1.07. The business has a 50 day simple moving average of $49.73 and a 200-day simple moving average of $51.80.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $11.77 million for the quarter, compared to analysts’ expectations of $9.11 million.

Institutional Trading of Merus

Several institutional investors have recently modified their holdings of MRUS. nVerses Capital LLC lifted its holdings in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,500 shares during the period. US Bancorp DE acquired a new stake in shares of Merus in the third quarter valued at $103,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 489 shares during the period. MML Investors Services LLC acquired a new stake in shares of Merus in the third quarter valued at $206,000. Finally, Farallon Capital Management LLC acquired a new stake in shares of Merus in the second quarter valued at $237,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.